| Literature DB >> 27889929 |
Florence Lacaille1, Sabine Irtan2, Laurent Dupic3, Cécile Talbotec1, Fabrice Lesage3, Virinie Colomb1, Nadège Salvi4, Florence Moulin3, Frédérique Sauvat2, Yves Aigrain2, Yann Revillon2, Olivier Goulet1, Christophe Chardot2.
Abstract
Our aim was to describe our achievements in pediatric intestinal transplantation (ITx) and define areas for improvement. After a period (1987-1990) of nine isolated small bowel transplants (SBTx) where only one patient survived with her graft, 110 ITx were performed on 101 children from 1994 to 2014: 60 SBTx, 45 liver-small bowel, four multivisceral (three with kidneys), and one modified multivisceral. Indications were short bowel syndrome (36), motility disorders (30), congenital enteropathies (34), and others (1). Induction treatment was introduced in 2000. Patient/graft survival with a liver-containing graft or SBTx was, respectively, 60/41% and 46/11% at 18 years. Recently, graft survival at 5/10 years was 44% and 31% for liver-containing graft and 57% and 44% for SBTx. Late graft loss occurred in 13 patients, and 7 of 10 retransplanted patients died. The main causes of death and graft loss were sepsis and rejection. Among the 55 currently living patients, 21 had a liver-containing graft, 19 a SBTx (17 after induction), and 15 were on parenteral nutrition. ITx remains a difficult procedure, and retransplantation even more so. Over the long term, graft loss was due to rejection, over-immunosuppression was not a significant problem. Multicenter studies on immunosuppression and microbiota are urgently needed.Entities:
Keywords: graft loss; intestinal transplantation; multivisceral transplantation; survival
Mesh:
Year: 2017 PMID: 27889929 DOI: 10.1111/tri.12894
Source DB: PubMed Journal: Transpl Int ISSN: 0934-0874 Impact factor: 3.782